Industry Supported Sessions Programmes

TUESDAY, MAY 23, 2017

INDUSTRY SYMPOSIUM 1 – THE JOURNEY CONTINUES: VACCINATION OF CHILDREN AND ADOLESCENTS IN EUROPE

Tuesday, May 23, 08:30-10:00, Hall A

INDUSTRY SYMPOSIUM SUPPORTED BY MERCK MSD

08:30-08:35 Welcome and Introduction

Chair Paolo Bonanni, Italy

08:35-08:55 Varicella Vaccines in Europe: Where We Are, Where We Need to Go

Chair Paolo Bonanni, Italy

08:55-09:00 Q&A

09:00-09:25 hexavalent Vaccines – What Is New in Europe?

Gary Marshall, USA

09:25-09:30 Q&A

09:30-09:55 HPV Vaccines- Successes and Challenges

Elmar Joura, Austria

09:55-10:00 Q&A

******

INDUSTRY SYMPOSIUM 2 – REDUCING THE IMPACT OF INVASIVE MENINGOCOCCAL DISEASE: MUCH ACHIEVED SO FAR BUT STILL A LOT MORE TO DO!

Tuesday, May 23, 10:30-12:00, Hall A

INDUSTRY SYMPOSIUM SUPPORTED BY PFIZER

Introduction

Prof Federico Martinón-Torres, Spain (co-Chair)
Dr Bennett Lee (co-Chair)

Clinical Features of Invasive Meningococcal Disease in Adolescents and the Rationale for Adolescent Vaccination
Prof Paolo Bonanni, Italy University of Florence

Prevention of Invasive Meningococcal Disease: Vaccine Options and Vaccine Strategies

Prof Markus Knuf, Germany Clinic for Children and Adolescents of Wiesbaden

Role of the Polysaccharide Capsule and factor H binding protein in Protecting Neisseria meningitidis From the Immune System

Dr Jamie Findlow, UK Public Health England

Evaluating the Value of Meningococcal Vaccine Programmes:  A Comprehensive Approach

Ms Claire Wright, UK Meningitis Research Foundation

Dr Koonal Shah, UK Office of Health Economics

Summary and Closing

Prof Federico Martinón-Torres, Spain (co-Chair)

******

INDUSTRY SYMPOSIUM 3 – PERTUSSIS CONTROL: A THOUGHOUT LIFE APPROACH

Tuesday, May 23, 13:00-14:30, Hall A

INDUSTRY SYMPOSIUM SUPPORTED BY SANOFI PASTEUR

Chairman

Prof. Federico Martinón-Torres
Translational Pediatrics and Infectious Diseases - Hospital Clínico Universitario de Santiago de Compostela, Spain

The changing face of pertussis - the role of epidemiology, diagnosis and vaccination

 Prof. Carl Heinz Wirsing von König
 Institute for Hygiene and Laboratory Medicine, Helios Klinikum Krefeld, Germany

Optimal vaccination schedule for lifelong pertussis control - a paediatrician's perspective

Prof. Ulrich Heininger,
University of Basel Children's Hospital, Division of Pediatric Infectious Diseases and Vaccinology, Switzerland

Confidence in vaccination among the public and healthcare professionals in Europe
Dr. Angus Thomson,Vaccine Confidence & Coverage, Public Affairs, Sanofi Pasteur Lyon, France

******

 

INDUSTRY SYMPOSIUM 4 –  EXPECTED AND UNEXPECTED; PCV’S IN EUROPEAN CHILDHOOD VACCINATION PROGRAMMES

Tuesday, May 23, 14:45-16:15, Hall A

INDUSTRY SYMPOSIUM SUPPORTED BY THE UNIVERSITY MEDICAL CENTRE UTRECHT

The timeslot of this Industry Symposium has been offered by GSK to the University Medical Centre Utrecht). Agenda and content of presentations have been developed independently by University Medical Centre Utrecht), with no input from GSK.

14:45-14:57 Introduction and data from The Netherlands: from carriage to impact after PCV introduction

Chair: Elizabeth Sanders

14:57-15:12 County specific data from PCV10 and PCV13 impact in Sweden

Birgitta Henriques Normark

15:12-15:27 Life lessons: Pneumonia hospitalizations in Scotland following the introduction of PCV in children

Harish Nair

15:27-15:45 Full public health impact or cherry-picking?

Arto Palmu

15:45-16:00 "Unexpected increase of pneumococcal meningitis after the introduction of PCV7 in France: Interaction of vaccination and reduction of antibiotic use

Matthieu Domenech de Cellès

16:00-16:15 Panel Q&A

******

INDUSTRY SYMPOSIUM 5 – EUROPEAN SOCIETY FOR PAEDIATRIC INFECTIOUS DISEASES

Tuesday, May 23, 16:45-18:15, Hall A

INDUSTRY SYMPOSIUM SUPPORTED BY GSK

16:45-16:50 Introduction

Thomas Breuer, Chief Medical Officer, GSK Biologics, Belgium

16:50-17:05 From “yes, doctor”, to “no, doctor”: the immunization debate between individual choices and collective good

Katie Attwell, Professor of Politics, Murdoch School of Politics and Public Affairs, University of Perth, Australia

17:05-17:20 “Don’t smoke, eat well, do physical activity and vaccinate”: the new public health paradigm of healthy living

Pierluigi Lopalco
Professor of Hygiene and Preventive Medicine, University of Pisa, Italy

17:20-17:35 “Be wise, immunize”: pediatricians as providers and ambassadors of the immunization culture

Roy Philip, Professor of Pediatrics and Neonatology, University Hospital Limerick, Ireland

17:35-17:50 “We are all in for lifecourse immunization”

Thomas Breuer

17:50-18:15 Discussion and Q&A

All

******

INDUSTRY SYMPOSIUM 6 – Coming Soon

Tuesday, May 23, 18:30-20:00, Hall A

INDUSTRY SYMPOSIUM SUPPORTED BY ASTRAZENECA

Coming Soon

******

INDUSTRY SYMPOSIUM 7 – THE CHALLENGE OF ANTIBIOTIC RESISTANCE: RESPONSIBLE MANAGEMENT OF RESPIRATORY TRACT INFECTIONS IN CHILDREN

Tuesday, May 23, 20:15-21:45, Madrid Hall

INDUSTRY SYMPOSIUM SUPPORTED BY SCHWABE

Viral RTIs: Situation mostly harmless – antibiotics mostly useless

Philip E. Tarr, MD, assistant professor

How children can benefit from a non-antibiotic alternative

Georg Seifert, MD, PhD, professor

 

Positively moving forward: Overview of clinical data on EPs® 7630

Wolfgang Kamin, MD, PhD, professor

******

WEDNESDAY, MAY 24, 2017

INDUSTRY SYMPOSIUM 8–- ASSESSING THE BENEFIT/RISK OF VACCINES: THE BALANCING ACT

Wednesday, May 24, 08:30-10:00, Hall A

INDUSTRY SYMPOSIUM SUPPORTED BY GSK

08:30-08:35 Welcome

Dr. Jens-Ulrich Stegmann (GSK)

08:35-08:50 Introduction to safety of vaccines

Dr. Jens-Ulrich Stegmann (GSK)

08:50-09:30 Case-study 1: Rotavirus vaccination and intussusception

Case-study 2: MMRV vaccination and increased fever after the first dose

Dr. Jens-Ulrich Stegmann (GSK), Role of the manufacturer

Dr. Michael Pfleiderer (non-GSK), Perspective of the authorities

Prof. Dr. Marco Safadi (non-GSK), Challenges for the vaccinator

09:30-10:00 Round table and interactive Q&A

All

******

INDUSTRY SYMPOSIUM 9 – UK EXPERIENCE WITH GROUP B MENINGOCOCCAL DISEASE: VACCINE EFFECTIVENESS, IMPACT, SURVEILLANCE AND SAFETY

Wednesday, May 24, 10:30-12:00, Hall A

INDUSTRY SYMPOSIUM SUPPORTED BY PUBLIC HEALTH ENGLAND

The timeslot of this Industry Symposium has been offered by GSK to the Public Health England). Agenda and content of presentations have been developed independently by Public Health England), with no input from GSK.

10:30-10:35 Introduction

Dr Shamez Ladhani, (Public Health England, UK)

10:35-10:55 Vaccine effectiveness and impact of 4CMenB after two years in England

Dr Mary Ramsay (Public Health England, UK)

10:55-11:15 Laboratory surveillance to monitor 4CMenB in infants and toddlers

Dr Jamie Findlow (Public Health England, UK)

11:15-11:35 4CMenB Safety: analysis after the first million infants vaccinated

Dr Philip Bryan (Medicines and Healthcare Products Regulatory Agency, UK)

11:35-11:50 Do infants need prophylactic paracetamol with 4CMenB?

Dr Shamez Ladhani, (Public Health England, UK)

11:50-12:00 Discussion and debate involving Faculty and Audience


******

INDUSTRY SYMPOSIUM 10 – WHAT REALLY MATTERS FOR PNEUMOCOCCAL VACCINES

Wednesday, May 24, 13:00-14:30, Hall A

INDUSTRY SYMPOSIUM SUPPORTED BY PFIZER

Chair: Prof. Juan Picazo, Spain

Co-chair: Prof. Heinz-Josef Schmitt, France

13:00 Welcome and Introduction

Prof. Heinz-Josef Schmitt, France

13:05 PCV13: pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) -global review

Prof. Juan Picazo, Spain

13:20 Role of vaccines containing serotype 19A in pneumococcal disease control 

Dr Mark van der Linden, Germany

13:40 Long-term impact of PCV13* on mucosal diseases

Prof. David Greenberg, Israel

14:05 Questions & Answers  

All

14:25 Conclusions

Prof. Juan Picazo, Spain & Prof. Heinz-Josef Schmitt, France

*PCV13: pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)

******

INDUSTRY SYMPOSIUM 11 – Coming Soon

Wednesday, May 24, 13:00-14:30, Madrid Hall

INDUSTRY SYMPOSIUM SUPPORTED BY ABBVIE

Coming Soon

Keep Me Updated